跳至主要内容
临床试验/NCT02423174
NCT02423174撤回不适用

Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery

Domain Surgical, Inc.0 个研究点开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility

研究概览

简要总结

The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for Total Mesorectal Excision Surgery.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed rectal cancer to the lower two-thirds of the rectum (higher and T2 N0 or N+)
  • Amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities
  • ECOG status ≤ 2
  • Life expectancy >3 months
  • Age ≥ 18 years old
  • Age ≤ 80 years old
  • Ability to provide written informed consent and HIPAA forms prior to admission to this study
  • Willingness to meet all of the expected requirements of this clinical protocol

排除标准

  • Patient with metastasis
  • History of radiotherapy or chemotherapy for the treatment of rectal cancer
  • Uremia - BUN>40
  • Hemodialysis
  • Existing urinary or fecal incontinence
  • Pregnant or lactating
  • Previously diagnosed coagulopathy or bleeding diathesis
  • Currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, Plavix, warfarin, NSAIDs, clopidogrel, ticlopidine or valproic acid
  • History of significant cardiac disorders that would necessitate special fluid management protocols
  • History of acute myocardial infarction and/or acute angina
  • INR >1.4 in the 24 hours prior to surgery
  • PTT >40 in the 24 hours prior to surgery
  • Platelet count <100K in the 24 hours prior to surgery

结局指标

主要结局

Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility

时间窗: 1 day after surgery

Safety and feasibility will be assessed by evaluating intra-operative serious adverse events, if any, and their relationship with the FMwand Ferromagnetic Surgical System

次要结局

  • Post-operative Drainage(Beginning day 2 after surgery and for the duration of the hospital stay, an expected average of 6 days)
  • Onset of urinary or fecal incontinence(Beginning day 2 after surgery and for the duration of the hospital stay, an expected average of 6 days)
  • Duration of Procedure(During Procedure)
  • Duration of TME resection(During procedure)
  • Evaluation of post-operative complications(12 weeks after surgery)

研究者

发起方
Domain Surgical, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验